• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在恒化器模型中，模拟人血浆浓度的头孢地尔对耐碳青霉烯革兰氏阴性杆菌的活性。

Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an Chemostat Model.

作者信息

Matsumoto Shuhei, Kanazawa Sachi, Sato Takafumi, Yamano Yoshinori

机构信息

Business Development, Shionogi & Co., Ltd., Osaka, Japan

Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan.

出版信息

Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01128-20.

DOI:10.1128/AAC.01128-20
PMID:32900685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7577172/
Abstract

Activities of cefiderocol under simulated human plasma concentrations at the recommended dosing regimen of 2 g every 8 h with a 3-h infusion were evaluated using an chemostat model. Against a total of 6 meropenem-resistant Gram-negative strains with cefiderocol MICs of 0.5 to 4 μg/ml, including metallo-β-lactamase producers and carbapenem-resistant , cefiderocol treatment showed a bactericidal effect within 8 h and sustained efficacy with no marked bacterial regrowth over 24 h.

摘要

使用恒化器模型评估了在每8小时2克、持续输注3小时的推荐给药方案下，模拟人体血浆浓度时头孢地尔的活性。针对总共6株对美罗培南耐药的革兰氏阴性菌，其头孢地尔最低抑菌浓度（MIC）为0.5至4微克/毫升，包括产金属β-内酰胺酶的菌株和耐碳青霉烯类菌株，头孢地尔治疗在8小时内显示出杀菌作用，并且在24小时内具有持续疗效，没有明显的细菌再生长。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f13/7577172/69354cb8a458/AAC.01128-20-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f13/7577172/27bab2e4a4e7/AAC.01128-20-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f13/7577172/69354cb8a458/AAC.01128-20-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f13/7577172/27bab2e4a4e7/AAC.01128-20-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f13/7577172/69354cb8a458/AAC.01128-20-f0002.jpg

相似文献

1
Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an Chemostat Model.在恒化器模型中，模拟人血浆浓度的头孢地尔对耐碳青霉烯革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01128-20.
2
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
3
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).头孢地尔罗的体外活性，一种铁载体头孢菌素，针对最近收集的临床相关碳青霉烯类药物不敏感的革兰氏阴性杆菌，包括丝氨酸碳青霉烯酶和金属β-内酰胺酶产生的分离株（SIDERO-WT-2014 研究）。
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.
4
Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).头孢菌素类铁载体头孢地尔的活性对来自北美和欧洲的近期临床相关革兰氏阴性杆菌的收集，包括耐碳青霉烯类分离株（SIDERO-WT-2014 研究）。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00093-17. Print 2017 Sep.
5
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.在加拿大重症监护病房中分离的革兰氏阴性杆菌的体外活性研究：新型铁载体头孢菌素头孢地尔。
Diagn Microbiol Infect Dis. 2020 May;97(1):115012. doi: 10.1016/j.diagmicrobio.2020.115012. Epub 2020 Feb 4.
6
Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.2014 年至 2016 年全球范围内收集的碳青霉烯类药物不敏感和多重耐药革兰氏阴性杆菌的头孢菌素类抗生素头孢地尔的活性。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01968-17. Print 2018 Feb.
7
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.头孢地尔（S-649266）对从希腊医院住院患者中分离出的耐碳青霉烯革兰氏阴性菌的活性。
J Antimicrob Chemother. 2017 Jun 1;72(6):1704-1708. doi: 10.1093/jac/dkx049.
8
Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.全球肠杆菌科、铜绿假单胞菌、鲍曼不动杆菌和嗜麦芽寡养单胞菌对头孢地尔罗耐药的流行情况：系统评价和荟萃分析。
Clin Microbiol Infect. 2024 Feb;30(2):178-188. doi: 10.1016/j.cmi.2023.08.029. Epub 2023 Sep 4.
9
Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.头孢地尔：一种针对多重耐药革兰氏阴性菌的新型头孢菌素策略。
Clin Infect Dis. 2022 Apr 9;74(7):1303-1312. doi: 10.1093/cid/ciab757.
10
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.头孢地尔在碳青霉烯类耐药鲍曼不动杆菌感染管理中的前瞻性作用：证据回顾。
Int J Antimicrob Agents. 2023 Aug;62(2):106882. doi: 10.1016/j.ijantimicag.2023.106882. Epub 2023 Jun 8.

引用本文的文献

1
efficacy of humanized regimen of flomoxef against extended-spectrum β-lactamase-producing and .氟莫头孢对产超广谱β-内酰胺酶和 的人化治疗方案的疗效。
Antimicrob Agents Chemother. 2023 Sep 19;67(9):e0025823. doi: 10.1128/aac.00258-23. Epub 2023 Aug 23.
2
Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.头孢地尔，一种铁载体头孢菌素，作为耐碳青霉烯类肠杆菌科细菌所致感染的一种治疗选择。
Infect Dis Ther. 2023 Mar;12(3):777-806. doi: 10.1007/s40121-023-00773-6. Epub 2023 Feb 25.
3
Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against using chemostat and murine infection models.

本文引用的文献

1
The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms.战斗正在进行：用于治疗多重耐药革兰氏阴性菌的新型β-内酰胺类药物
Curr Infect Dis Rep. 2020 Jan 13;22(1):1. doi: 10.1007/s11908-020-0710-9.
2
Metallo-β-lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods.肠杆菌科中的金属β-内酰胺酶耐药性是目前使用的抗菌药物敏感性测试方法的一个假象。
J Antimicrob Chemother. 2020 Apr 1;75(4):997-1005. doi: 10.1093/jac/dkz532.
3
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.
在使用恒化器和小鼠感染模型对头孢地尔进行人体模拟暴露的情况下，评估其持续疗效和耐药性的出现。
JAC Antimicrob Resist. 2022 May 3;4(3):dlac047. doi: 10.1093/jacamr/dlac047. eCollection 2022 Jun.
4
Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.头孢地尔治疗多重耐药革兰阴性菌：对现有证据的系统评价
Front Pharmacol. 2022 Apr 12;13:896971. doi: 10.3389/fphar.2022.896971. eCollection 2022.
5
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.头孢地尔罗：在严重革兰氏阴性细菌感染中的评价。
Drugs. 2021 Sep;81(13):1559-1571. doi: 10.1007/s40265-021-01580-4. Epub 2021 Aug 24.
头孢地尔罗酯对广泛临床重要革兰氏阴性菌的体外活性。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S544-S551. doi: 10.1093/cid/ciz827.
4
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.头孢地尔罗：一种新型铁载体头孢菌素的发现、化学结构和体内特征。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S538-S543. doi: 10.1093/cid/ciz826.
5
Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models.头孢地尔洛的药效学研究，一种新型的注射用铁载体头孢菌素，在鼠大腿和肺部感染模型中的研究。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.02031-18. Print 2019 Sep.
6
Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.新型铁载体头孢菌素头孢地尔的肉汤微量稀释 MIC 用缺铁阳离子调整 Mueller-Hinton 肉汤测定的可重复性。
Diagn Microbiol Infect Dis. 2019 Aug;94(4):321-325. doi: 10.1016/j.diagmicrobio.2019.03.003. Epub 2019 Mar 23.
7
Shifting Gears: The Future of Polymyxin Antibiotics.换挡：多粘菌素类抗生素的未来
Antibiotics (Basel). 2019 Apr 12;8(2):42. doi: 10.3390/antibiotics8020042.
8
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
9
Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients.氨基糖苷类药物药代动力学-药效学分析在儿科癌症患者中的应用。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.01781-17. Print 2018 Apr.
10
Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.头孢地尔（S-649266）在鼠大腿感染模型中对多种革兰氏阴性细菌的人源化暴露的疗效。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01022-17. Print 2017 Nov.